Nkarta Inc (NKTX)

$2.07 -0.05 (-2.36%)
Market Cap 150.57M
Revenue (ttm) 0.00
Net Income (ttm) -108.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 542,900
Avg Vol 542,008
Day's Range N/A - N/A
Shares Out 71.03M
Stochastic %K 13%
Beta 0.76
Analysts Strong Sell
Price Target $12.40

Company Profile

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for...

Industry: Biotechnology
Sector: Healthcare
Phone: 925 407 1049
Address:
1150 Veterans Boulevard, South San Francisco, United States
vu_jade
vu_jade Sep. 9 at 9:25 PM
$NKTX smelling news coming! We are ready!
0 · Reply
vu_jade
vu_jade Sep. 9 at 6:10 PM
$NKTX fell like an announcement will be coming soon .. see you at $4
0 · Reply
Lukey63
Lukey63 Sep. 9 at 12:56 AM
$NKTX In a world of rallying stocks, this keeps falling down the stairs.
1 · Reply
vu_jade
vu_jade Sep. 8 at 7:53 PM
$NKTX pay us our $4 and we’ll go somewhere else
0 · Reply
vu_jade
vu_jade Sep. 8 at 6:55 PM
$NKTX here’s an idea .. close shop and pay us out your $4+ in cash ..
0 · Reply
vu_jade
vu_jade Sep. 8 at 6:46 PM
$NKTX buy low .. sell high
0 · Reply
vu_jade
vu_jade Sep. 8 at 4:46 PM
$NKTX added. Thanks for the sale price
0 · Reply
vu_jade
vu_jade Sep. 5 at 9:45 PM
$NKTX long 50k ready for $5
0 · Reply
elmarklimke
elmarklimke Sep. 5 at 8:24 PM
$NKTX rocket is taking off ....
0 · Reply
vu_jade
vu_jade Sep. 5 at 3:42 PM
$NKTX big pop coming
0 · Reply
Latest News on NKTX
Nkarta to Participate in a September Investor Conference

Sep 2, 2025, 8:01 AM EDT - 7 days ago

Nkarta to Participate in a September Investor Conference

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Aug 12, 2025, 4:01 PM EDT - 4 weeks ago

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Jul 23, 2025, 8:01 AM EDT - 6 weeks ago

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Jul 22, 2025, 12:40 AM EDT - 7 weeks ago

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Jun 6, 2025, 8:52 AM EDT - 3 months ago

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

May 15, 2025, 3:46 PM EDT - 4 months ago

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

May 14, 2025, 4:01 PM EDT - 4 months ago

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Nkarta to Participate in an April Investor Conference

Apr 1, 2025, 8:01 AM EDT - 5 months ago

Nkarta to Participate in an April Investor Conference

Nkarta: Grinding Lower, Trying To Find Support

Mar 31, 2025, 10:41 AM EDT - 5 months ago

Nkarta: Grinding Lower, Trying To Find Support

Nkarta: Betting On The Turnaround

Mar 31, 2025, 10:15 AM EDT - 5 months ago

Nkarta: Betting On The Turnaround

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Mar 27, 2025, 12:50 PM EDT - 5 months ago

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Mar 26, 2025, 4:01 PM EDT - 5 months ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

Feb 25, 2025, 8:01 AM EST - 7 months ago

Nkarta to Participate in March Investor Conferences

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Dec 5, 2024, 6:01 AM EST - 9 months ago

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in an Upcoming Investor Conference

Nov 26, 2024, 7:02 AM EST - 10 months ago

Nkarta to Participate in an Upcoming Investor Conference

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nov 7, 2024, 4:02 PM EST - 10 months ago

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

Oct 8, 2024, 9:07 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

AMN MRNA

Nkarta to Participate in Upcoming Investor Conference

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conference

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Aug 14, 2024, 3:08 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 9:03 PM EDT - 1 year ago

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Jul 24, 2024, 6:00 AM EDT - 1 year ago

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Jul 16, 2024, 6:01 AM EDT - 1 year ago

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Jun 27, 2024, 6:00 AM EDT - 1 year ago

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Jun 13, 2024, 4:01 PM EDT - 1 year ago

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta: Finally An Attractive Valuation

May 25, 2024, 2:20 AM EDT - 1 year ago

Nkarta: Finally An Attractive Valuation

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Apr 27, 2024, 10:27 AM EDT - 1 year ago

Nkarta: Down 50% Since March With A Clinical Catalyst Ahead

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 8, 2024, 12:55 PM EDT - 1 year ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Apr 5, 2024, 3:35 PM EDT - 1 year ago

The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Nkarta to Participate in Upcoming Investor Conferences

Apr 3, 2024, 4:02 PM EDT - 1 year ago

Nkarta to Participate in Upcoming Investor Conferences

Nkarta: NK Cell Therapy Advancement On Two Fronts

Mar 25, 2024, 4:03 PM EDT - 1 year ago

Nkarta: NK Cell Therapy Advancement On Two Fronts

Nkarta Announces Pricing of $240 Million Underwritten Offering

Mar 25, 2024, 6:30 AM EDT - 1 year ago

Nkarta Announces Pricing of $240 Million Underwritten Offering

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Mar 21, 2024, 4:01 PM EDT - 1 year ago

Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Mar 13, 2024, 1:22 PM EDT - 1 year ago

Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders

Nkarta: Possible Upside From H1 Update, If Positive

Jan 25, 2024, 12:12 PM EST - 1 year ago

Nkarta: Possible Upside From H1 Update, If Positive

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Dec 9, 2023, 8:31 PM EST - 1 year ago

Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nov 9, 2023, 4:02 PM EST - 1 year ago

Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conferences

Nov 7, 2023, 8:02 AM EST - 2 years ago

Nkarta to Participate at Upcoming Investor Conferences

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Oct 17, 2023, 11:47 AM EDT - 2 years ago

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Oct 17, 2023, 7:01 AM EDT - 2 years ago

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Oct 16, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Aug 10, 2023, 7:01 AM EDT - 2 years ago

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

Nkarta to Participate at Upcoming Investor Conference

Aug 3, 2023, 8:02 AM EDT - 2 years ago

Nkarta to Participate at Upcoming Investor Conference

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Jul 5, 2023, 4:02 PM EDT - 2 years ago

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Jun 27, 2023, 7:01 AM EDT - 2 years ago

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Jun 26, 2023, 4:01 PM EDT - 2 years ago

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Jun 10, 2023, 10:47 AM EDT - 2 years ago

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

May 11, 2023, 4:02 PM EDT - 2 years ago

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

vu_jade
vu_jade Sep. 9 at 9:25 PM
$NKTX smelling news coming! We are ready!
0 · Reply
vu_jade
vu_jade Sep. 9 at 6:10 PM
$NKTX fell like an announcement will be coming soon .. see you at $4
0 · Reply
Lukey63
Lukey63 Sep. 9 at 12:56 AM
$NKTX In a world of rallying stocks, this keeps falling down the stairs.
1 · Reply
vu_jade
vu_jade Sep. 8 at 7:53 PM
$NKTX pay us our $4 and we’ll go somewhere else
0 · Reply
vu_jade
vu_jade Sep. 8 at 6:55 PM
$NKTX here’s an idea .. close shop and pay us out your $4+ in cash ..
0 · Reply
vu_jade
vu_jade Sep. 8 at 6:46 PM
$NKTX buy low .. sell high
0 · Reply
vu_jade
vu_jade Sep. 8 at 4:46 PM
$NKTX added. Thanks for the sale price
0 · Reply
vu_jade
vu_jade Sep. 5 at 9:45 PM
$NKTX long 50k ready for $5
0 · Reply
elmarklimke
elmarklimke Sep. 5 at 8:24 PM
$NKTX rocket is taking off ....
0 · Reply
vu_jade
vu_jade Sep. 5 at 3:42 PM
$NKTX big pop coming
0 · Reply
NYBomba
NYBomba Sep. 5 at 3:18 PM
$NKTX - next step up in price will be fueled by the Golden Cross on Monday… ☮️
0 · Reply
hopeteen
hopeteen Sep. 5 at 9:30 AM
$NKTX Even the stock's message volume is very low and the message senders are always the same people. No new news or catalyst on the horizon. This is a negative indicator, imo.
1 · Reply
vu_jade
vu_jade Sep. 4 at 4:11 PM
$NKTX 4 years worth of cash
0 · Reply
vu_jade
vu_jade Sep. 4 at 2:55 PM
$NKTX pop coming
0 · Reply
vu_jade
vu_jade Sep. 3 at 4:04 AM
$NKTX might have to add more .. full +
0 · Reply
vu_jade
vu_jade Sep. 2 at 6:27 PM
$NKTX added more $2.10 .. easy double potential 500%
1 · Reply
pleiades108
pleiades108 Sep. 2 at 12:52 PM
$NKTX I'll wait for 1.90 for a new entry.
0 · Reply
Highbred
Highbred Aug. 29 at 7:51 PM
$NKTX 👑
0 · Reply
vu_jade
vu_jade Aug. 28 at 3:52 PM
$NKTX feels like a big move coming:: 🆙
2 · Reply
vu_jade
vu_jade Aug. 26 at 6:18 PM
$NKTX full position….
1 · Reply
Lukey63
Lukey63 Aug. 26 at 5:01 PM
$NKTX this stock price is a joke. With all the overvalued shit on the exchanges. I just don’t get it. Is everyone waiting for the golden cross? Yes, I am talking my book.
1 · Reply
vu_jade
vu_jade Aug. 26 at 1:31 AM
$NKTX cash runway to 2029 Market making news will come out that will 4-5 X this before then.
0 · Reply